Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haworth, C S
Right arrow Articles by Webb, A K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haworth, C S
Right arrow Articles by Webb, A K
Thorax 2001;56:314-316 ( April )

Short paper

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis C S Hawortha, P L Selbyb, J E Adamsc, E B Mawerb, A W Horrocksa, A K Webba

a Manchester Adult Cystic Fibrosis Unit, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester M23 9LT, UK, b Department of Medicine, University of Manchester, Manchester Royal Infirmary, Manchester M13 9WL, UK, c Clinical Radiology, Imaging Science and Biomedical Engineering, University of Manchester, Manchester M13 9PT, UK

Correspondence to: Professor A K Webb the5webbs{at}hotmail.com

Received 5 June 2000; Returned to authors 3 October 2000; Revised version received 8 November 2000; Accepted for publication 18 December 2000

BACKGROUND---Low bone mineral density (BMD) is prevalent in adults with cystic fibrosis. The aim of this study was to assess the effect of intravenous pamidronate on BMD in these subjects.
METHODS---Patients were invited to participate if they had a BMD Z score of -2 or less in the lumbar spine, proximal femur, or distal forearm. Patients were randomised to receive either 30 mg intravenous pamidronate every 3 months + 1 g calcium daily (pamidronate group) or 1 g calcium daily (control group). All pancreatic insufficient patients were prescribed oral vitamin D supplements.
RESULTS---After 6 months of treatment the pamidronate group (n=13) showed a significant increase in absolute BMD compared with the control group (n=15) in the lumbar spine (mean difference 5.8% (CI 2.7% to 8.9%)) and total hip (mean difference 3.0% (CI 0.3% to 5.6%)). However, the pamidronate group showed a reduction in BMD compared with the control group in the distal forearm (mean difference -1.7% (CI -3.7% to 0.3%)). The use of pamidronate was associated with a high incidence of bone pain in non-corticosteroid treated individuals.
CONCLUSION---Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use.


Keywords: cystic fibrosis; bone mineral density; osteoporosis; pamidronate; bisphosphonates

© 2001 by Thorax


This article has been cited by other articles:


Home page
 ChestHome page
A. Papaioannou, C. C. Kennedy, A. Freitag, G. Ioannidis, J. O'Neill, C. Webber, M. Pui, Y. Berthiaume, H. R. Rabin, N. Paterson, et al.
Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)
Chest, October 1, 2008; 134(4): 794 - 800.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Knox and J Britton
Thorax 1996-2002
Thorax, December 1, 2006; 61(12): 1020 - 1021.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. M. Aris, P. A. Merkel, L. K. Bachrach, D. S. Borowitz, M. P. Boyle, S. L. Elkin, T. A. Guise, D. S. Hardin, C. S. Haworth, M. F. Holick, et al.
Guide to Bone Health and Disease in Cystic Fibrosis
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1888 - 1896.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S P Conway, B Oldroyd, A Morton, J G Truscott, and D G Peckham
Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study
Thorax, August 1, 2004; 59(8): 699 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Aris, G. E. Lester, M. Caminiti, A. D. Blackwood, M. Hensler, R. K. Lark, T. M. Hecker, J. B. Renner, U. Guillen, S. A. Brown, et al.
Efficacy of Alendronate in Adults with Cystic Fibrosis with Low Bone Density
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 77 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A.A. Ionescu and E. Schoon
Osteoporosis in chronic obstructive pulmonary disease
Eur. Respir. J., November 2, 2003; 22(46_suppl): 64s - 75s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. L. Elkin, S. Vedi, S. Bord, N. J. Garrahan, M. E. Hodson, and J. E. Compston
Histomorphometric Analysis of Bone Biopsies from the Iliac Crest of Adults with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1470 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
C S Haworth, P L Selby, A W Horrocks, E B Mawer, J E Adams, and A K Webb
A prospective study of change in bone mineral density over one year in adults with cystic fibrosis
Thorax, August 1, 2002; 57(8): 719 - 723.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & British Thoracic Society